Previous 10 | Next 10 |
Medical device company Inari Medical (NASDAQ:NARI) is trading higher on Tuesday after Piper Sandler initiated its coverage with an Overweight recommendation citing multiple growth drivers for a favorable set-up. The analysts led by Adam C. Maeder point out that the maker of the ClotTriever me...
Gainers: Inari Medical (NARI) +6%. Rhythm Pharmaceuticals (RYTM) +5%. Adaptive Biotechnologies (ADPT) +5%. The RealReal (REAL) +5%. Esperion Therapeutics (ESPR) +4%. Losers: GoodRx Holdings (GDRX) -6%. AlloVir (ALVR) -5%. Caribou Biosciences (CRBU) -5%. Arrowhead Pharmaceuticals (AR...
OKAMI MEDICAL ANNOUNCES FDA 510(k) CLEARANCE OF THE LOBO-7 and LOBO-9 VASCULAR OCCLUDERS TO ADDRESS A WIDE RANGE OF PERIPHERAL EMBOLIZATION CASES PR Newswire ALISO VIEJO, Calif. , June 7, 2022 /PRNewswire/ -- Okami Medical Inc., a medical device company f...
The following slide deck was published by Inari Medical, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Inari Medical, Inc. 2022 Q1 - Results - Earnings Call Presentation
IRVINE, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced the publication of its first ever “Eth...
Inari Medical, Inc. (NARI) Q1 2022 Earnings Conference Call May 04, 2022 4:30 PM ET Company Participants Caroline Corner - IR Bill Hoffman - CEO Mitch Hill - CFO Drew Hykes - COO Tom Tu - CMO Conference Call Participants Travis Steed - Bank of America Cecilia Furlong - Morgan Stanley Larry Bi...
Image source: The Motley Fool. Inari Medical, Inc. (NASDAQ: NARI) Q1 2022 Earnings Call May 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Inari Medical, Inc. (NARI) Q1 2022 Earnings Call Transcript
Inari Medical press release (NASDAQ:NARI): Q1 GAAP EPS of -$0.06 beats by $0.04. Revenue of $86.75M (+51.1% Y/Y) beats by $3.14M. Shares -0.64%. For the full year 2022, we are revising our revenue guidance to a range of $360 million to $370 million, an increase of $10 million from our origina...
IRVINE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ...
Gainers: Finch Therapeutics (FNCH) +46%. Zymeworks (ZYME) +44%. Lantheus (LNTH) +13%. BeiGene (BGNE) +12%. Inari Medical (NARI) +11%. Losers: Accolade (ACCD) -55%. Aldeyra Therapeutics (ALDX) -15%. Venus Concept (VERO) -14%. Bio...
News, Short Squeeze, Breakout and More Instantly...
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024...
Hagens Berman Encourages NARI Investors with Substantial Losses to Contact Firm Before July 12, 2024 Deadline San Francisco, California--(Newsfile Corp. - June 26, 2024) - Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses no...
2024-06-01 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...